Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: Who, when and how

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 1-7

  Klyuchnikov, E ^a   Bacher, U ^a,b   Kroll, T ^c   Shea, T C ^d   Lazarus, H M ^e   Bredeson, C ^f   Fenske, T S ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Allogeneic hematopoietic cell transplantation; Diffuse large B cell lymphoma; Myeloablative conditioning; Reducedintensity conditioning

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACETUZUMAB; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; FOSTAMATINIB; GEMCITABINE; IBRUTINIB; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOTUZUMAB OZOGAMICIN; MELPHALAN; OFATUMUMAB; OXALIPLATIN; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TOSITUMOMAB; UNINDEXED DRUG; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; GRAFT VERSUS LYMPHOMA EFFECT; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LARGE CELL LYMPHOMA; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA;

ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; RECURRENCE; REGISTRIES; SALVAGE THERAPY; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84891874313     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.72     Document Type: Review

References (53)

1. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395-403.
2. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426-432.
3. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85.
4. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
5. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256-4262.
6. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Impact of pretransplant conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsisve diffuse large B-cell lymphoma and grade-III follicular lymphoma. Biol Blood Marrow Transplant 2013; 19: 746-753.
7. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35-45.
8. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 2012; 91: 931-939.
9. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
10. Gisselbrecht C, Glass B, Mounier N, Singh GD, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.
11. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-4087.
12. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069-6076.
13. Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011; 35: 183-187.
14. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1287-1294.
15. Vose JM, Carter S, Burns LJ, Ayala E, Press O, Moskowitz CH et al. Phase III randomized study of rituximab/carmustin, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tostitumomab/BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0401 Trial. J Clin Oncol 2013; 31: 1662-1668.
16. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 1653-1659.
17. Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poorrisk diffuse large cell lymphoma. Biol Blood Marrow Transplant 2012; 18: 441-450.
18. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706-4714.
19. Gisselbrecht C, Schmitz N, Mounier N, Singh GD, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ Diffuse Large B-Cell Lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462-4469.
20. Gordon L, Weller E, Armand P, Devine S, Holland H, Mason J et al. A Phase II study of CT-011, an anti-PD-1 antibody, after auSCT in recurrent/refractory DLBCL: first analysis of progression-free-survival (PFS), overall survival (OS) and toxicity (TOX). Ann Oncol 2011; 22: (Abstract 063).
21. Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80: 127-132.
22. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009 27: 4371-4377.
23. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085-2093.
24. Cartron G, Thieblemont C, Solal-Celigny P, Morschhhauser F, Haioun C, Bouabdallah R et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients-first results from a Phase II study in patients with relapsed/refractory DLBCL and MCL. Blood 2010; 116: (Abstract 2878).
25. Coiffier B, Bosly A, Wu K, Verhoef G, Koen V, Martinelli G et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter Phase II study. Blood 2010; 116: (Abstract 3955).
26. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
27. Smith SM, van BK, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740-4746.
28. Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, LaCasce A et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Blood 2011; 118: (Abstract 1635).
29. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
30. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058-5066.
31. Jacobsen E, Advani R, Oki Y, Sharman J, Horwitz S, Forero-Torres A et al. A Phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin Lymphomas: interim results. Blood 2012; 120: (Abstract 2746).
32. Ogura M, Ando K, Niitsu N, Kim S, Ohmachi K, Takahashi N et al. A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2012; 30: (Abstract 8023).
33. Wilson WH, Gerecitano J, Goy A, de Vos S, Kenkre V, Barr P et al. The Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC Subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open label, Phase II study. Blood 2012; 120: (Abstract 686).
34. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a Phase I/II study evaluating the immunoconjugate Inotuzumab Ozogamicin with Rituximab. J Clin Oncol 2013; 31: 573-583.
35. Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW et al. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54: 277-283.
36. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 965-972.
37. Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223-230.
38. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009; 15: 1455-1464.
39. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579-590.
40. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144-4152.
41. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373-6378.
42. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935-1940.
43. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
44. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
45. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419-2423.
46. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871.
47. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535-3542.
48. Butcher BW, Collins Jr RH. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 2005; 36: 1-17.
49. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-1838.
50. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419.
51. Durr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res 2010; 70: 10170-10181.
52. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012; 30: 3202-3208.
53. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci 2013; 110: 1398-1403.